based on 3 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 3 analysts offering long term price targets for Marksans Pharma Ltd. An average target of ₹330.33
Source: S&P Global Market Intelligence
Marksans Pharma Ltd price forecast by 3 analysts
Upside of8.18%
High
₹376
Target
₹330.33
Low
₹265
Marksans Pharma Ltd target price ₹330.33, a slight upside of 8.18% compared to current price of ₹309.15. According to 3 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Marksans Pharma Ltd revenue growth forecast
Expected growth rate Q1, FY2026:41.23%
Forecast
Actual
Including amortisation and stock based compensations
Marksans Pharma Ltd EPS growth forecast
EPS estimate Q1, FY2026:56.50%
Forecast
Actual
Source: S&P Global Market Intelligence
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | + 11.42 % |
3 Month Return | + 38.93 % |
1 Year Return | + 119.68 % |
Market Stats | |
Previous Close | ₹305.35 |
Open | ₹305.35 |
Volume | 19.46L |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹13,837.35Cr |
P/E Ratio | 39.86 |
PEG Ratio | 51.77 |
Market Cap | ₹13,837.35 Cr |
P/B Ratio | 5.62 |
EPS | 6.95 |
Dividend Yield | 0.4 |
Sector | Pharmaceuticals |
ROE | 11.46 |
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
BUY | ₹13,837.35 Cr | 387.13% | 0.51 | ₹314 Cr | ₹2,177 Cr | |
NA | ₹64.17 Cr | 258.28% | 0.50 | NA | NA | |
NA | ₹123.98 Cr | 53.7% | 0.69 | NA | NA | |
NA | ₹94.27 Cr | 188.71% | 0.51 | NA | NA | |
NA | ₹1,388.42 Cr | 84.92% | 0.51 | ₹25 Cr | ₹212 Cr |
Organisation | Marksans Pharma Ltd |
Headquarters | Mumbai |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Marksans Pharma Ltd
Marksans Pharma's standalone net sales for September 2024 reached Rs 308.63 crore, up 50.79% YoY. Net profit surged 102% to Rs 63.20 crore, with EBITDA rising 57.11%. The stock has delivered impressive returns of 92.63% over the last six months and 118.07% over the past year.
Marksans Pharma Reports Strong Q2 FY25 Financials - 12 Nov, 2024
Marksans Pharma's Q2 FY25 results show significant growth, with revenue rising 20.84% YoY to Rs 641.92 crore and net profit increasing 16.56% YoY. The stock gained 2.70% following the announcement, reflecting positive investor sentiment.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
FII Holding Up
Foreign Institutions have increased holdings from 7.71% to 10.43% in Sep 2024 quarter
Price Rise
In the last 3 months, MARKSANS stock has moved up by 38.9%
Revenue Rich
Revenue is up for the last 3 quarters, 576.54 Cr → 652.98 Cr (in ₹), with an average increase of 6.0% per quarter
MF Holding Up
Mutual Funds have increased holdings from 2.82% to 3.02% in Sep 2024 quarter
Profit Spike
Netprofit is up for the last 3 quarters, 78.29 Cr → 96.72 Cr (in ₹), with an average increase of 10.0% per quarter
Best in 3 Years
In the last 3 years, MARKSANS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
Best in 1 Year
In the last 1 year, MARKSANS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
Promoter Holding Unchanged
Promoters holdings remained unchanged at 43.87% of holdings in Sep 2024 quarter
Retail Holding Down
Retail Investor have decreased holdings from 33.78% to 30.71% in Sep 2024 quarter
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 43.87% | 0.00 | |
Foreign Institutions | 10.43% | 35.16 | |
Mutual Funds | 3.02% | 7.44 | |
Retail Investors | 30.71% | ||
Others | 11.96% | 1.24 |
Marksans Pharma Ltd in the last 5 years
Lowest (4.67x)
April 1, 2020
Today (39.86x)
November 19, 2024
Industry (54.42x)
November 19, 2024
Highest (46.60x)
January 24, 2018
Marksans Pharma Ltd’s net profit jumped 15.8% since last year same period to ₹96.72Cr in the Q2 2024-2025. On a quarterly growth basis, Marksans Pharma Ltd has generated 8.98% jump in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending March 2024, Marksans Pharma Ltd has declared dividend of ₹0.60 - translating a dividend yield of 0.36%.
Read More about DividendsBearish
Neutral
Bullish
Marksans Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
Marksans Pharma Ltd (MARKSANS) share price today is ₹309.15
Marksans Pharma Ltd is listed on NSE
Marksans Pharma Ltd is listed on BSE
PE Ratio of Marksans Pharma Ltd is 39.86
PE ratio = Marksans Pharma Ltd Market price per share / Marksans Pharma Ltd Earnings per share
Today’s traded volume of Marksans Pharma Ltd(MARKSANS) is 19.46L.
Today’s market capitalisation of Marksans Pharma Ltd(MARKSANS) is ₹13837.35Cr.
Marksans Pharma Ltd(MARKSANS | Price |
---|---|
52 Week High | ₹328.8 |
52 Week Low | ₹130 |
Marksans Pharma Ltd(MARKSANS) share price is ₹309.15. It is down -5.98% from its 52 Week High price of ₹328.8
Marksans Pharma Ltd(MARKSANS) share price is ₹309.15. It is up 137.81% from its 52 Week Low price of ₹130
Marksans Pharma Ltd(MARKSANS | Returns |
---|---|
1 Day Returns | 3.8% |
1 Month Returns | 11.42% |
3 Month Returns | 38.93% |
1 Year Returns | 119.68% |